Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thrombosis and inflammatory bowel disease.

Peter M Irving1, K John Pasi, David S Rampton

  • 1Centre for Gastroenterology, Institute of Cell and Molecular Science, Barts and The London NHS Trust, United Kingdom.

Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|October 7, 2005
PubMed
Summary

Thrombosis, or blood clot formation, is increasingly linked to inflammatory bowel diseases (IBD). Research explores how blood clotting may initiate and worsen inflammation in conditions like ulcerative colitis and Crohn

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mirikizumab is equally effective in ustekinumab-exposed and ustekinumab-naïve patients with UC: a multicenter real-world cohort.

Crohn's & colitis 360·2026
Same author

Mirikizumab four-year sustained and durable efficacy and safety in ulcerative colitis: Final findings from the LUCENT-3 open-label extension study.

Inflammatory bowel diseases·2026
Same author

Rapid symptomatic improvement with etrasimod in ulcerative colitis: a post-hoc analysis of the ELEVATE UC program.

Inflammatory bowel diseases·2026
Same author

Comparative Efficacy and Safety of Advanced Therapies in Maintenance Treatment of Adult Patients with Moderate-to-Severe Crohn's Disease: A Systematic Literature Review and Network Meta-Analysis.

Advances in therapy·2026
Same author

Effectiveness of etrasimod on disease activity and patient-reported outcomes in ulcerative colitis-EFFECT-UC: a non-interventional, multinational, prospective cohort study protocol.

BMJ open·2025
Same author

Design and rationale for the VICTRIVA study: A randomized, double-blind, phase 3b study of vedolizumab in combination with upadacitinib in Crohn's disease.

Contemporary clinical trials communications·2025

Area of Science:

  • Gastroenterology
  • Hematology
  • Immunology

Background:

  • The interplay between thrombosis and inflammation is a growing area of research.
  • Inflammatory bowel diseases (IBD), including ulcerative colitis and Crohn's disease, are associated with an increased risk of thromboembolic events.
  • A resurgence in research investigates the role of the hemostatic system in IBD pathogenesis.

Purpose of the Study:

  • To review the current understanding of the relationship between thrombosis and inflammatory bowel disease.
  • To explore the potential role of thrombosis in the initiation and maintenance of IBD inflammation.
  • To examine how hemostatic system abnormalities and interactions may influence IBD complications and treatment.

Main Methods:

  • Literature review of studies on thrombosis, inflammation, and inflammatory bowel disease.

Related Experiment Videos

  • Analysis of research on coagulation system abnormalities and platelet dysfunction in IBD patients.
  • Examination of proposed mechanisms linking hemostasis to inflammation in IBD.

    • Main Results:

    • Patients with IBD exhibit a higher frequency of thromboembolic complications.
    • Evidence suggests thrombosis may contribute to the initiation and perpetuation of inflammation in IBD.
    • Abnormalities in the coagulation system and platelet dysfunction are observed in IBD patients.
    • Hemostatic processes can exert proinflammatory effects in the context of IBD.

    Conclusions:

    • The interaction between thrombosis and inflammation is significant in inflammatory bowel disease.
    • Understanding these interactions is crucial for managing thromboembolic complications and underlying inflammation in IBD.
    • Further research into hemostatic system modulation may offer novel therapeutic strategies for IBD.